First Eagle Investment Management’s Pacira BioSciences PCRX Stock Holding History

First Eagle Investment Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-103,081	Closed	-$3.48M	–	422
2023 Q4	$3.48M	Sell	103,081 -104,551	-50%	-$3.06M	0.01%	287
2023 Q3	$6.37M	Sell	207,632 -36,640	-15%	-$1.32M	0.02%	184
2023 Q2	$9.79M	Buy	244,272 +67,847	+38%	+$2.81M	0.03%	98
2023 Q1	$7.2M	Buy	176,425 +93,412	+113%	+$3.72M	0.02%	105
2022 Q4	$3.21M	Buy	83,013 +4,482	+6%	+$218K	0.01%	194
2022 Q3	$4.18M	Buy	78,531 +8,706	+12%	+$484K	0.01%	97
2022 Q2	$4.07M	Buy	69,825 +22,104	+46%	+$1.45M	0.01%	89
2022 Q1	$3.64M	Buy	47,721 +22,889	+92%	+$1.53M	0.01%	87
2021 Q4	$1.49M	Buy	+24,832	New	+$1.37M	﹤0.01%	97

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

First Eagle Investment Management's PCRX Position: Q1 2024 in Review

First Eagle Investment Management sold out of Pacira BioSciences (PCRX) in Q1 2024, closing a stake of 103,081 shares — an estimated $3.48M sold.

First Eagle Investment Management first reported a position in PCRX in Q4 2021 and held it in 9 quarters. The position peaked at $9.79M in Q2 2023. 271 funds tracked by Wall St. Rank hold PCRX as of Q1 2024.

First Eagle Investment Management reported no remaining Pacira BioSciences position as of Q1 2024 after selling out during the quarter.
First Eagle Investment Management sold 103,081 Pacira BioSciences shares in Q1 2024, an estimated $3.48M.
First Eagle Investment Management first reported a position in Pacira BioSciences in Q4 2021 and held it in 9 quarters.
First Eagle Investment Management's Pacira BioSciences position peaked at $9.79M in Q2 2023.
271 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2024.

Based on First Eagle Investment Management's 13F filing for Q1 2024, filed 9 May 2024.